Daewoong Pharmaceutical
Amy Hyoyoung Kim is a seasoned business development professional with extensive experience in the pharmaceutical industry. Currently serving as a BD Manager in the Investor Relations Team at Daewoong Pharmaceutical since March 2023, Amy is responsible for overseeing licensing out and alliance management for late-stage novel assets. Prior to this role, Amy spent over seven years at Hanmi Pharmaceuticals as Group Leader of the BD Group, where achievements included executing licensing agreements for oncology assets and leading due-diligence and negotiation processes. Amy has also worked as a Project/Alliance Manager, coordinating project development and implementing risk-mitigation strategies. Earlier in 2015, Amy held a translation role at CJ HEALTHCARE LIMITED, handling regulatory documents in Korean and English. Amy holds a Bachelor of Science degree in Pre-medicine from Liberty University and has foundational education in Human Performance from PennWest Edinboro.
Daewoong Pharmaceutical
Establish in 1945, Daewoong Pharmaceuticals Co., Ltd. is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals for both domestic and international markets. Through our strong M&S divisions, Daewoong has the largest prescription drug sales in the South Korean market. Presently, we commercialize 10 blockbuster products. In addition, we have built a strong internal core competency for new drug development and have expanded regional and global collaborations with international partners. To reach our goal to become a global health care company, Daewoong has expanded international operations establishing branches offices throughout Asia and research centers in the US, China, and India. Currently, Daewoong is constructing a new manufacturing facility under cGMP guidelines to meet the needs of our global partners.